- Home
- VRDN vs IMCR Comparison
VRDN vs IMCR Comparison
Compare VRDN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- IMCR
- Stock Information
- Founded
- VRDN 2006
- IMCR 2008
- Country
- VRDN United States
- IMCR United Kingdom
- Employees
- VRDN N/A
- IMCR N/A
- Industry
- VRDN Medical Specialities
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRDN Health Care
- IMCR Health Care
- Exchange
- VRDN Nasdaq
- IMCR Nasdaq
- Market Cap
- VRDN 1.3B
- IMCR 1.5B
- IPO Year
- VRDN N/A
- IMCR 2021
- Fundamental
- Price
- VRDN $14.34
- IMCR $31.15
- Analyst Decision
- VRDN Strong Buy
- IMCR Buy
- Analyst Count
- VRDN 11
- IMCR 10
- Target Price
- VRDN $38.50
- IMCR $58.13
- AVG Volume (30 Days)
- VRDN 750.1K
- IMCR 508.6K
- Earning Date
- VRDN 08-07-2025
- IMCR 08-07-2025
- Dividend Yield
- VRDN N/A
- IMCR N/A
- EPS Growth
- VRDN N/A
- IMCR N/A
- EPS
- VRDN N/A
- IMCR N/A
- Revenue
- VRDN $302,000.00
- IMCR $333,581,000.00
- Revenue This Year
- VRDN N/A
- IMCR $26.82
- Revenue Next Year
- VRDN $17,102.33
- IMCR $8.15
- P/E Ratio
- VRDN N/A
- IMCR N/A
- Revenue Growth
- VRDN 4.86
- IMCR 25.75
- 52 Week Low
- VRDN $9.90
- IMCR $23.15
- 52 Week High
- VRDN $27.20
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- VRDN 50.32
- IMCR 44.46
- Support Level
- VRDN $14.11
- IMCR $30.83
- Resistance Level
- VRDN $16.05
- IMCR $37.56
- Average True Range (ATR)
- VRDN 0.74
- IMCR 1.58
- MACD
- VRDN -0.13
- IMCR -0.59
- Stochastic Oscillator
- VRDN 20.18
- IMCR 15.64
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.